A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

被引：28
|
作者：
Sangro, Bruno
Park, Joong-Won
Dela Cruz, Christine Marie
Anderson, Jeffrey
Lang, Lixin
Neely, Jaclyn
Shaw, James W.
Cheng, Ann-Lii
机构：
[1] Clin Univ Navarra & CIBERHD, Liver Unit, Pamplona, Spain
[2] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4147
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
    Yau, T.
    Park, J. W.
    Finn, R. S.
    Cheng, A-L.
    Mathurin, P.
    Edeline, J.
    Kudo, M.
    Han, K-H.
    Harding, J. J.
    Merle, P.
    Rosmorduc, O.
    Wyrwicz, L.
    Schott, E.
    Choo, S. P.
    Kelley, R. K.
    Begic, D.
    Chen, G.
    Neely, J.
    Anderson, J.
    Sangro, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 874 - +
  • [2] CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
    Edeline, Julien
    Yau, Thomas
    Park, Joong-Won
    Kudo, Masatoshi
    Han, Kwang-Hyub
    Mathurin, Philippe
    Merle, Philippe
    Finn, Richard S.
    Mueller, Tobias
    Taylor, Fiona
    Greenwood, Mike
    Begic, Damir
    Tschaika, Marina
    Yip, Christine
    Pranschke, Emma
    Cocks, Kim
    Thompson, Gwilym
    Blum, Steven I.
    Wisniewski, Tami
    Sangro, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [3] Nivolumab (Nivo) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): the CheckMate 040 Study
    Melero, Ignacio
    Sangro, Bruno
    Yau, Thomas
    Hsu, Chiun
    Kudo, Masatoshi
    Crocenzi, Todd S.
    Kim, Tae-You
    Choo, Su-pin
    Trojan, Jorg
    Meyer, Timothy
    Welling, Theodore
    Yeo, Winnie
    Chopra, Akhil
    Anderson, Jeffrey
    Delacruz, Christine
    Lang, Lixin
    Neely, Jaclyn
    Tang, Hao
    El-Khoueiry, Anthony B.
    HEPATOLOGY, 2016, 64 (06) : 1124A - 1124A
  • [4] Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom M.
    Trojan, Jorg
    Cebon, Jonathan S.
    Liem, Andre K. D.
    Lipton, Lara Rachel
    Gupta, Charu
    Wu, Benjamin
    Litten, Jason B.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Zhu, A. X.
    Finn, R. S.
    Mulcahy, M. F.
    Gurtler, J. S.
    Sun, W.
    Schwartz, J. D.
    Rojas, P.
    Dontabhaktuni, A.
    Youssoufian, H.
    Stuart, K. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial
    Neely, Jaclyn
    Yao, Jin
    Kudo, Masatoshi
    Finn, Richard S.
    Sangro, Bruno
    Melero, Ignacio
    El-Khoueiry, Anthony
    Tschaika, Marina
    Begic, Damir
    Sama, Ashwin
    Doshi, Parul
    Yau, Thomas
    Kelley, Robin Kate
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
    Crocenzi, Todd S.
    El-Khoueiry, Anthony B.
    Yau, Thomas Cheung
    Melero, Ignacio
    Sangro, Bruno
    Kudo, Masatoshi
    Hsu, Chiun
    Trojan, Jorg
    Kim, Tae -You
    Choo, Su -Pin
    Meyer, Tim
    Kang, Yoon-Koo
    Yeo, Winnie
    Chopra, Akhil
    Baakili, Adyb
    Dela Cruz, Christine Marie
    Lang, Lixin
    Neely, Jaclyn
    Welling, Theodore
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Nivolumab in sorafenib-naive and - experienced patients with advanced hepatocellular carcinoma (HCC): checkMate 040 study
    Trojan, J.
    Crocenzi, T. S.
    El-Khoueiry, A. B.
    Yau, T.
    Melero, I.
    Sangro, B.
    Kudo, M.
    Hsu, C.
    Kim, T. -Y.
    Choo, S. -P.
    Meyer, T.
    Kang, Y. -K.
    Yeo, W.
    Chopra, A.
    Baakili, A.
    dela Cruz, C.
    Lang, L.
    Neely, J.
    Welling, T. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 210 - +
  • [9] CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
    Sangro, B.
    Park, J.
    Finn, R.
    Cheng, A.
    Mathurin, P.
    Edeline, J.
    Kudo, M.
    Han, K.
    Harding, J.
    Merle, P.
    Rosmorduc, O.
    Wyrwicz, L.
    Schott, E.
    Choo, S.
    Kelley, R.
    Begic, D.
    Chen, G.
    Neely, J.
    Tschaika, M.
    Yau, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S241 - S242
  • [10] Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
    Cheng, A. -L.
    Finn, R. S.
    Qin, S.
    Han, K. -H.
    Ikeda, K.
    Piscaglia, F.
    Baron, A.
    Park, J. -W.
    Han, G.
    Jassem, J.
    Blanc, J. F.
    Vogel, A.
    Komov, D.
    Evans, T. J.
    Lopez, C.
    Dutcus, C.
    Ren, M.
    Kraljevic, S.
    Tamai, T.
    Kudo, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 211 - 211
12345